In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America | Zendy

Daniel J. Diekema | Zendy; Michael A. Pfaller | Zendy; S. A. Messer | Zendy; A. Houston | Zendy; R. J. Hollis | Zendy; Gary V. Doern | Zendy; Ronald N. Jones | Zendy

Open Access

In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America

Author(s) -

Daniel J. Diekema,

Michael A. Pfaller,

S. A. Messer,

A. Houston,

R. J. Hollis,

Gary V. Doern,

Ronald N. Jones

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.9.2236

Subject(s) - fluconazole , itraconazole , azole , microbiology and biotechnology , biology , medicine , pharmacology , antifungal

We compared the in vitro activity of BMS-207147, an investigational triazole, with those of itraconazole and fluconazole against 613 clinical bloodstream isolates ofCandida spp. collected from SENTRY participating hospitals during 1997 and 1998. Overall, BMS-207147 was the most active azole against allCandida spp. While both BMS-207147 and itraconazole displayed a stepwise decrease in activity against isolates for which the fluconazole MICs were elevated, BMS-207147 had two- to fourfold greater activity than itraconazole both againstCandida spp. that were dose-dependently fluconazole susceptible and against those that were fluconazole resistant.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research